1. Home
  2. ENVB vs WORX Comparison

ENVB vs WORX Comparison

Compare ENVB & WORX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ENVB
  • WORX
  • Stock Information
  • Founded
  • ENVB 1994
  • WORX N/A
  • Country
  • ENVB United States
  • WORX United States
  • Employees
  • ENVB N/A
  • WORX N/A
  • Industry
  • ENVB Biotechnology: Pharmaceutical Preparations
  • WORX Services-Misc. Amusement & Recreation
  • Sector
  • ENVB Health Care
  • WORX Consumer Discretionary
  • Exchange
  • ENVB Nasdaq
  • WORX Nasdaq
  • Market Cap
  • ENVB 3.0M
  • WORX 2.5M
  • IPO Year
  • ENVB N/A
  • WORX N/A
  • Fundamental
  • Price
  • ENVB $0.97
  • WORX $0.31
  • Analyst Decision
  • ENVB Strong Buy
  • WORX
  • Analyst Count
  • ENVB 1
  • WORX 0
  • Target Price
  • ENVB $10.00
  • WORX N/A
  • AVG Volume (30 Days)
  • ENVB 325.7K
  • WORX 8.1M
  • Earning Date
  • ENVB 08-14-2025
  • WORX 08-14-2025
  • Dividend Yield
  • ENVB N/A
  • WORX N/A
  • EPS Growth
  • ENVB N/A
  • WORX N/A
  • EPS
  • ENVB N/A
  • WORX N/A
  • Revenue
  • ENVB N/A
  • WORX $2,838,404.00
  • Revenue This Year
  • ENVB N/A
  • WORX N/A
  • Revenue Next Year
  • ENVB N/A
  • WORX N/A
  • P/E Ratio
  • ENVB N/A
  • WORX N/A
  • Revenue Growth
  • ENVB N/A
  • WORX N/A
  • 52 Week Low
  • ENVB $0.85
  • WORX $0.26
  • 52 Week High
  • ENVB $8.33
  • WORX $3.31
  • Technical
  • Relative Strength Index (RSI)
  • ENVB 40.51
  • WORX 46.96
  • Support Level
  • ENVB $0.85
  • WORX $0.28
  • Resistance Level
  • ENVB $1.06
  • WORX $0.36
  • Average True Range (ATR)
  • ENVB 0.10
  • WORX 0.06
  • MACD
  • ENVB -0.02
  • WORX 0.00
  • Stochastic Oscillator
  • ENVB 19.34
  • WORX 11.88

About ENVB Enveric Biosciences Inc.

Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.

About WORX SCWorx Corp.

SCWorx Corp is a provider of data content and services related to the repair, normalization, and interoperability of information for healthcare providers, as well as big data analytics for the healthcare industry. Its software enables a healthcare provider to simplify and organize its data, allows the data to be utilized across multiple internal software applications, and provides the basis for sophisticated data analytics. The company has developed and markets healthcare information technology solutions and associated services to improve healthcare processes and information flow within hospitals and other healthcare facilities.

Share on Social Networks: